
Chinese General Practice ›› 2025, Vol. 28 ›› Issue (05): 587-593.DOI: 10.12114/j.issn.1007-9572.2023.0924
Special Issue: 衰弱最新文章合辑
• Original Research • Previous Articles Next Articles
Received:2024-04-10
Revised:2024-07-09
Published:2025-02-15
Online:2024-11-25
Contact:
MA Qing
通讯作者:
马清
作者简介:作者贡献:
石小天提出主要研究目标,负责研究的构思与设计,研究的实施,撰写论文;石小天、杨一帆、李旭、窦国泽进行数据的收集与整理,统计学处理,图、表的绘制与展示;王珊、杨华昱进行论文的修订;马清负责文章的质量控制与审查,对文章整体负责,监督管理。
基金资助:CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2023.0924
| 组别 | 例数 | 性别[例(%)] | 年龄[M(P25,P75),岁] | BMI [M(P25,P75),kg/m2] | 文化程度[例(%)] | 多重用药[例(%)] | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| 男 | 女 | 高中以下 | 高中 | 大学及以上 | 是 | 否 | ||||
| 无衰弱组 | 341 | 259(75.95) | 82(24.05) | 71.0(65.0,80.0) | 24.37(22.42,26.21) | 7(2.05) | 23(6.74) | 311(91.20) | 85(24.93) | 256(75.07) |
| 衰弱/衰弱前期组 | 213 | 154(72.30) | 59(25.70) | 79.0(68.0,86.0) | 23.91(21.92,26.10) | 12(5.63) | 14(6.57) | 187(87.79) | 103(48.36) | 110(51.64) |
| 检验统计量值 | 0.920a | -6.166 | -1.398 | 5.078a | 32.104a | |||||
| P值 | 0.337 | <0.001 | 0.162 | 0.079 | <0.001 | |||||
| 组别 | 独居[例(%)] | 吸烟[例(%)] | 饮酒[例(%)] | MNA-SF评分[M(P25,P75),分] | ACCI [M(P25,P75),分] | 糖化血红蛋白[M(P25,P75),%] | ||||
| 是 | 否 | 是 | 否 | 是 | 否 | |||||
| 无衰弱组 | 28(8.21) | 313(91.79) | 46(13.49) | 295(86.51) | 109(31.96) | 232(68.04) | 14.00(13.00,14.00) | 3.00(2.00,4.00) | 5.97(5.67,6.42) | |
| 衰弱/衰弱前期组 | 19(8.92) | 194(91.08) | 28(13.15) | 185(86.85) | 54(25.35) | 159(74.65) | 13.00(12.00,14.00) | 4.00(3.00,5.00) | 5.89(5.60,6.24) | |
| 检验统计量值 | 0.085a | 0.013a | 2.761a | -4.920 | -6.569 | -1.768 | ||||
| P值 | 0.771 | 0.908 | 0.097 | <0.001 | <.001 | 0.077 | ||||
| 组别 | 白蛋白(g/L) | 白细胞计数[M(P25,P75),×109/L] | 中性粒细胞绝对值[M(P25,P75),×109/L] | 淋巴细胞绝对值[M(P25,P75),×109/L] | 单核细胞绝对值[M(P25,P75),×109/L] | 红细胞[M(P25,P75),×1012/L] | 血红蛋白[M(P25,P75),g/L] | |||
| 无衰弱组 | 44.07±2.57 | 6.14(5.28,7.25) | 3.47(2.81,4.30) | 2.21(1.71,2.65) | 0.29(0.23,0.38) | 4.73(4.46,4.96) | 148.00(140.00,155.00) | |||
| 衰弱/衰弱前期组 | 42.96±2.91 | 6.21(5.23,7.38) | 3.52(2.87,4.39) | 2.10(1.62,2.51) | 0.29(0.23,0.35) | 4.61(4.22,4.83) | 142.00(132.00,151.00) | |||
| 检验统计量值 | 4.169b | -0.115 | -0.817 | -2.497 | -0.732 | -3.786 | -4.856 | |||
| P值 | <0.001 | 0.909 | 0.414 | 0.013 | 0.464 | <0.001 | <0.001 | |||
| 组别 | 红细胞体积分布宽度[M(P25,P75),fL] | 血小板计数[M(P25,P75),×109/L] | 血小板体积分布宽度[M(P25,P75),%] | 总胆固醇[M(P25,P75),μmol/L] | 三酰甘油[M(P25,P75),μmol/L] | 高密度脂蛋白[M(P25,P75),μmol/L] | ||||
| 无衰弱组 | 43.60(41.70,45.20) | 211.00(183.00,244.00) | 11.50(10.70,12.50) | 4.80(4.20,5.57) | 1.26(0.98,1.71) | 1.19(1.03,1.37) | ||||
| 衰弱/衰弱前期组 | 44.30(42.60,45.90) | 206.00(172.00,244.00) | 11.50(10.40,12.50) | 4.65(3.85,5.45) | 1.14(0.85,1.68) | 1.23(1.02,1.48) | ||||
| 检验统计量值 | -2.702 | -1.541 | -0.868 | -2.560 | -2.896 | -1.030 | ||||
| P值 | 0.007 | 0.123 | 0.386 | 0.010 | 0.004 | 0.303 | ||||
| 组别 | 低密度脂蛋白[M(P25,P75),μmol/L] | NLR [M(P25,P75)] | dNLR [M(P25,P75)] | HRR [M(P25,P75)] | MLR [M(P25,P75)] | PLR [M(P25,P75)] | PRP [M(P25,P75)] | |||
| 无衰弱组 | 2.93(2.51,3.47) | 1.54(1.19,2.06) | 1.74(1.39,2.35) | 3.41(3.16,3.61) | 0.14(0.10,0.18) | 96.70(77.25,118.22) | 0.21(0.18,0.24) | |||
| 衰弱/衰弱前期组 | 2.67(2.19,3.26) | 1.73(1.30,2.31) | 2.00(1.53,2.63) | 3.23(2.97,3.48) | 0.14(0.11,0.19) | 96.40(79.61,124.30) | 0.21(0.18,0.27) | |||
| 检验统计量值 | -4.220 | -2.681 | -2.955 | -4.942 | -1.340 | -0.905 | -2.037 | |||
| P值 | <0.001 | 0.007 | 0.003 | <0.001 | 0.180 | 0.365 | 0.042 | |||
Table 1 Clinical features in the elderly of non-frail group versus frail/pre-frail group
| 组别 | 例数 | 性别[例(%)] | 年龄[M(P25,P75),岁] | BMI [M(P25,P75),kg/m2] | 文化程度[例(%)] | 多重用药[例(%)] | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| 男 | 女 | 高中以下 | 高中 | 大学及以上 | 是 | 否 | ||||
| 无衰弱组 | 341 | 259(75.95) | 82(24.05) | 71.0(65.0,80.0) | 24.37(22.42,26.21) | 7(2.05) | 23(6.74) | 311(91.20) | 85(24.93) | 256(75.07) |
| 衰弱/衰弱前期组 | 213 | 154(72.30) | 59(25.70) | 79.0(68.0,86.0) | 23.91(21.92,26.10) | 12(5.63) | 14(6.57) | 187(87.79) | 103(48.36) | 110(51.64) |
| 检验统计量值 | 0.920a | -6.166 | -1.398 | 5.078a | 32.104a | |||||
| P值 | 0.337 | <0.001 | 0.162 | 0.079 | <0.001 | |||||
| 组别 | 独居[例(%)] | 吸烟[例(%)] | 饮酒[例(%)] | MNA-SF评分[M(P25,P75),分] | ACCI [M(P25,P75),分] | 糖化血红蛋白[M(P25,P75),%] | ||||
| 是 | 否 | 是 | 否 | 是 | 否 | |||||
| 无衰弱组 | 28(8.21) | 313(91.79) | 46(13.49) | 295(86.51) | 109(31.96) | 232(68.04) | 14.00(13.00,14.00) | 3.00(2.00,4.00) | 5.97(5.67,6.42) | |
| 衰弱/衰弱前期组 | 19(8.92) | 194(91.08) | 28(13.15) | 185(86.85) | 54(25.35) | 159(74.65) | 13.00(12.00,14.00) | 4.00(3.00,5.00) | 5.89(5.60,6.24) | |
| 检验统计量值 | 0.085a | 0.013a | 2.761a | -4.920 | -6.569 | -1.768 | ||||
| P值 | 0.771 | 0.908 | 0.097 | <0.001 | <.001 | 0.077 | ||||
| 组别 | 白蛋白(g/L) | 白细胞计数[M(P25,P75),×109/L] | 中性粒细胞绝对值[M(P25,P75),×109/L] | 淋巴细胞绝对值[M(P25,P75),×109/L] | 单核细胞绝对值[M(P25,P75),×109/L] | 红细胞[M(P25,P75),×1012/L] | 血红蛋白[M(P25,P75),g/L] | |||
| 无衰弱组 | 44.07±2.57 | 6.14(5.28,7.25) | 3.47(2.81,4.30) | 2.21(1.71,2.65) | 0.29(0.23,0.38) | 4.73(4.46,4.96) | 148.00(140.00,155.00) | |||
| 衰弱/衰弱前期组 | 42.96±2.91 | 6.21(5.23,7.38) | 3.52(2.87,4.39) | 2.10(1.62,2.51) | 0.29(0.23,0.35) | 4.61(4.22,4.83) | 142.00(132.00,151.00) | |||
| 检验统计量值 | 4.169b | -0.115 | -0.817 | -2.497 | -0.732 | -3.786 | -4.856 | |||
| P值 | <0.001 | 0.909 | 0.414 | 0.013 | 0.464 | <0.001 | <0.001 | |||
| 组别 | 红细胞体积分布宽度[M(P25,P75),fL] | 血小板计数[M(P25,P75),×109/L] | 血小板体积分布宽度[M(P25,P75),%] | 总胆固醇[M(P25,P75),μmol/L] | 三酰甘油[M(P25,P75),μmol/L] | 高密度脂蛋白[M(P25,P75),μmol/L] | ||||
| 无衰弱组 | 43.60(41.70,45.20) | 211.00(183.00,244.00) | 11.50(10.70,12.50) | 4.80(4.20,5.57) | 1.26(0.98,1.71) | 1.19(1.03,1.37) | ||||
| 衰弱/衰弱前期组 | 44.30(42.60,45.90) | 206.00(172.00,244.00) | 11.50(10.40,12.50) | 4.65(3.85,5.45) | 1.14(0.85,1.68) | 1.23(1.02,1.48) | ||||
| 检验统计量值 | -2.702 | -1.541 | -0.868 | -2.560 | -2.896 | -1.030 | ||||
| P值 | 0.007 | 0.123 | 0.386 | 0.010 | 0.004 | 0.303 | ||||
| 组别 | 低密度脂蛋白[M(P25,P75),μmol/L] | NLR [M(P25,P75)] | dNLR [M(P25,P75)] | HRR [M(P25,P75)] | MLR [M(P25,P75)] | PLR [M(P25,P75)] | PRP [M(P25,P75)] | |||
| 无衰弱组 | 2.93(2.51,3.47) | 1.54(1.19,2.06) | 1.74(1.39,2.35) | 3.41(3.16,3.61) | 0.14(0.10,0.18) | 96.70(77.25,118.22) | 0.21(0.18,0.24) | |||
| 衰弱/衰弱前期组 | 2.67(2.19,3.26) | 1.73(1.30,2.31) | 2.00(1.53,2.63) | 3.23(2.97,3.48) | 0.14(0.11,0.19) | 96.40(79.61,124.30) | 0.21(0.18,0.27) | |||
| 检验统计量值 | -4.220 | -2.681 | -2.955 | -4.942 | -1.340 | -0.905 | -2.037 | |||
| P值 | <0.001 | 0.007 | 0.003 | <0.001 | 0.180 | 0.365 | 0.042 | |||
| 因素 | β | SE | Wald χ2值 | P值 | OR(95%CI) |
|---|---|---|---|---|---|
| MNA-SF评分 | -0.34 | 0.08 | -4.36 | <0.001 | 0.71(0.61~0.83) |
| ACCI | 0.35 | 0.08 | 4.33 | <0.001 | 1.42(1.21~1.66) |
| HRR | -0.81 | 0.34 | -2.40 | 0.016 | 0.44(0.23~0.86) |
| 多重用药(以是为参考) | |||||
| 否 | -0.62 | 0.21 | -2.93 | 0.003 | 0.54(0.36~0.81) |
Table 2 Multivariate Logistic regression analysis on influencing factors of frailty/pre-frailty in the elderly
| 因素 | β | SE | Wald χ2值 | P值 | OR(95%CI) |
|---|---|---|---|---|---|
| MNA-SF评分 | -0.34 | 0.08 | -4.36 | <0.001 | 0.71(0.61~0.83) |
| ACCI | 0.35 | 0.08 | 4.33 | <0.001 | 1.42(1.21~1.66) |
| HRR | -0.81 | 0.34 | -2.40 | 0.016 | 0.44(0.23~0.86) |
| 多重用药(以是为参考) | |||||
| 否 | -0.62 | 0.21 | -2.93 | 0.003 | 0.54(0.36~0.81) |
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
中华医学会老年医学分会,《中华老年医学杂志》编辑委员会. 老年人衰弱预防中国专家共识(2022)[J]. 中华老年医学杂志,2022,41(5):503-511. DOI:10.3760/cma.j.issn.0254-9026.2022.05.001.
|
| [13] |
中国老年医学学会营养与食品安全分会,中国循证医学中心,《中国循证医学杂志》编辑委员会,等. 老年患者家庭营养管理中国专家共识(2017版)[J]. 中国循证医学杂志,2017,17(11):1251-1259. DOI:10.7507/1672-2531.201707095.
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [1] | AN Yanhong, WANG Shidong, LI Xiaoran, GUO Jiayang, WANG Zhe, SHA Peilin, MENG Yijun, LI Xiaoxuan, SHI Xue, YU Zexing, XIAO Yonghua. Study on Risk Factors and Nomogram Prediction Model for Diabetic Kidney Disease: Based on Contrast-enhanced Ultrasound Technology [J]. Chinese General Practice, 2026, 29(21): 2995-3003. |
| [2] | SONG Zhenzhen, CHEN Yang, WANG Jiwen, LIU Huishan, SHEN Simeng, SUN Ying, CHEN Xing. Study of Maternal Risk Factors Associated with Neonatal Asphyxia in Late Preterm and Term Infants [J]. Chinese General Practice, 2026, 29(20): 2874-2878. |
| [3] | LI Chaohui, LIU Hui, WANG Kai. Identification of Factors Associated with Persistent Atrial Fibrillation and Development of a Classification Model [J]. Chinese General Practice, 2026, 29(20): 2846-2853. |
| [4] | YANG Xiaofeng, LI Xianwen, WU Yanfeng, ZHANG Qian, CHEN Juan, ZHAO Fengjiao. Association of Serum Vascular Endothelial Cadherin Levels with the Risk of Post-stroke Cognitive Impairment in Patients with Acute Ischemic Stroke [J]. Chinese General Practice, 2026, 29(20): 2867-2873. |
| [5] | ZHANG Huifang, CHEN Cunchuan, FAN Boyang, SUN Wenning, WANG Yingjie, ZHANG Ao, ZHAO Yang, WANG Haipeng. Study on the Service Capability of Primary Care Doctors to Integrate Medical and Preventive Services and Its Influencing Factors in Shandong Province [J]. Chinese General Practice, 2026, 29(19): 2711-2716. |
| [6] | ZHAO Huili, LU Lina, ZHUO Ya, WANG Xin. Clinical Characteristics and Risk Factors for Recurrence of Cryptogenic Organizing Pneumonia [J]. Chinese General Practice, 2026, 29(19): 2648-2655. |
| [7] | PANG Shu, SUN ying, JIANG Chunyan. Comparison of the Effectiveness of Fried's Frailty Phenotype and the FRAIL Scale in Assessing Pre-frailty among Community-dwelling Older Adults Undergoing Health Examinations [J]. Chinese General Practice, 2026, 29(19): 2664-2670. |
| [8] | NIE Jiahui, LI Guojuan, HAO Zhuoqun, DU Qiaorong, LIU Penghong, LIU Zhifen, LIU Sha, ZHANG Aixia, WANG Yanfang. Heterogeneity and Influencing Factors of Cognitive Function Impairment in Patients with Major Depressive Disorder [J]. Chinese General Practice, 2026, 29(17): 2340-2346. |
| [9] | ZHENG Renkuo, HUA Fei. The Correlation between Metabolic Dysfunction-associated Steatotic Liver Disease and Papillary Thyroid Carcinoma [J]. Chinese General Practice, 2026, 29(15): 2029-2036. |
| [10] | LIU Fan, CHEN Qiuyu, LI Jing. Development and Validation of a Nighttime Hypertension Screening Model for Subclinical High-risk Populations: a Single-center Cohort Study [J]. Chinese General Practice, 2026, 29(15): 1998-2005. |
| [11] | ZHEN Rui, GU Xufang, GAO Shengwei, ZHANG Bowen, REN Zhenjuan, YANG Ruixuan. Burden of Cardiovascular Diseases Attributable to Metabolic Risk Factors in China 1990—2021 and Projected Trends from 2022 to 2035 [J]. Chinese General Practice, 2026, 29(15): 2077-2083. |
| [12] | LIU Longxiao, XU Yuan, CHEN Yanyu, XUE Qi, FANG Yunlong, LUO Ruili, LI Yanqi, WANG Jinping, TAO Qingwen. Analysis of Clinical Characteristics and Influencing Factors of Rheumatoid Arthritis with Pain Combined with Central Sensitization [J]. Chinese General Practice, 2026, 29(14): 1858-1866. |
| [13] | WANG Siman, ZHANG Mengchu, LI Wen, XU Ai, XU Jin, GUO Rui, YAN Haixia. Research on the Construction of a Risk Prediction Model for Primary Hypertension with Left Ventricular Hypertrophy Based on TCM Syndromes and Pulse Graph Parameters [J]. Chinese General Practice, 2026, 29(14): 1840-1848. |
| [14] | HU Jiaqi, LI Duan, FANG Hao, FAN Xingying, DU Wei, ZHOU Hanni. Study on Predictive Model of Non-genetic Risk Factors for Hyperuricemia in a Physical Examination Cohort [J]. Chinese General Practice, 2026, 29(10): 1324-1333. |
| [15] | YU Xinyan, MA Zhong, CAO Fan, SU Peng, LIN Ying, ZHANG Haicheng. Predicting the Risk of Depression in Elderly Patients with Cardiovascular Metabolic Diseases Using Single-lead Wearable Electrocardiography at the Community Level [J]. Chinese General Practice, 2026, 29(10): 1300-1310. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||